HUMAN MOTOR PATTERNS S.R.L.

Musculoskeletal disorders represent one of the most widespread, economically costly, and consequential categories of health conditions globally. They affect workers across every industrial sector, professional athletes and recreational ones, elderly populations navigating the physical challenges of ageing, and people at every stage of recovery from injury or surgery. Despite this scale, the diagnosis and treatment of musculoskeletal conditions has remained heavily dependent on clinical intuition and observational assessment — approaches that are valuable but inherently limited in precision and objectivity. Human Motor Patterns — HMP — is an Italian innovative startup that has developed a patented medical device designed to change this picture. At the heart of HMP's technology is machine learning applied to movement analysis. The device captures detailed, high-resolution data on how a person moves — the kinematics and dynamics of walking, lifting, turning, reaching, and any other physical task relevant to the clinical question — and applies trained algorithms to identify deviations from healthy motor patterns. These deviations may indicate elevated injury risk before any clinical symptom has appeared, an early-stage pathology that conventional assessment would miss, or a specific functional limitation that should guide a rehabilitation programme. The combination of objective movement data and AI-powered interpretation gives clinicians a precision diagnostic tool that both complements and extends their existing assessment capabilities. This is not a consumer self-monitoring device. HMP's solution is designed to be deployed by specialist clinicians — physiotherapists, sports medicine physicians, occupational health professionals, rehabilitation specialists — who use the technology to deliver a meaningfully higher standard of musculoskeletal care. Faster and more objective diagnosis, rehabilitation protocols personalised to the individual's specific movement deficits, and rigorous tracking of functional recovery over time are the clinical outcomes the platform is built to enable. A landmark milestone came in August 2025 when HMP was granted a European patent, providing formal recognition of the novelty and inventive step of its approach and the intellectual property protection needed to build a durable commercial position in a competitive and well-resourced medical technology market. The European patent is described by the company as an epochal milestone for the sector — validation that the approach represents genuine scientific and engineering novelty rather than an incremental improvement on existing diagnostic methods. The company's growth strategy is centred on partnership and ecosystem development, building relationships with clinical institutions, rehabilitation centres, sports medicine organisations, workplace health services, and industrial health and safety providers who can extend the platform's reach and demonstrate its impact across the diverse populations most affected by musculoskeletal disorders.